First-line management of advanced or metastatic clear cell renal cancer: How long should immunotherapy and/or anti-angiogenic therapy last? What are the criteria for stopping or continuing treatment? (notice n° 504515)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 00693cam a2200145 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121083948.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Borchiellini, Delphine |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | First-line management of advanced or metastatic clear cell renal cancer: How long should immunotherapy and/or anti-angiogenic therapy last? What are the criteria for stopping or continuing treatment? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 19 |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 10 | Special Issue 1 | 2024-06-25 | p. 9-16 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2024-HS1-page-9?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2024-HS1-page-9?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux